Casdin Partners GP, LLC's Form 4 filing
Standard Biotools Inc.LAB · filed Aug 15, 2025
- Accession no.
- 0000919574-25-004979
- Filed
- Aug 15, 2025, 9:18 PM ET
- Trade date
- Aug 13-15, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $443.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Casdin Partners GP, LLCCIK 0001534260 | Director, 10% Owner |
| Casdin Capital, LLCCIK 0001534261 | Director, 10% Owner |
| Casdin EliCIK 0001534264 | Director, 10% Owner |
| Casdin Partners Master Fund, L.P.CIK 0001534265 | Director, 10% Owner |
| Casdin Private Growth Equity Fund, L.P.CIK 0001823061 | Director |
| Casdin Private Growth Equity Fund GP, LLCCIK 0001864554 | Director |
| Casdin Private Growth Equity Fund II, L.P.CIK 0001891102 | Director |
| Casdin Private Growth Equity Fund II GP, LLCCIK 0001919480 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | Common Stock | PPurchaseAcquired | +75,000 | $1.31F1 | +$98,280 | 59,466,780 | Indirect | |
| Aug 14, 2025 | Common Stock | PPurchaseAcquired | +133,220 | $1.21 | +$161,542.57 | 59,600,000 | Indirect | |
| Aug 15, 2025 | Common Stock | PPurchaseAcquired | +150,000 | $1.22F3 | +$183,210 | 59,750,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.3075 to $1.3118. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2179 to $1.2232. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.